All News

 
NEWS – COVID-19 Pharmacovigilance Support Webinar: How to Adapt Hosting, Conduction of Remote Audits and Inspections

We are pleased to share the news that the registration to PrimeVigilance COVID-19 Pharmacovigilance Support Webinar titled “How to Adapt Hosting, Conduction of Remote Audits and Inspections”, taking place on June 30, 2020 is now open.

Published
9 June 2020.

Read more
 
Press Release – Strategic Collaboration to Drive Pharmacovigilance Leadership in Intelligent Automation

PrimeVigilance, an Ergomed company, is pleased to announce its collaboration with Automation Anywhere and DataRobot to advance robotic processes and machine learning.

Published
18 May 2020.

Read more
 
Press Release – PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program

PrimeVigilance is pleased to share ERGOMED plc Press Release and to part of front against coronavirus

Published
30 March 2020.

Read more
 
NEWS – PrimeVigilance response to Zagreb earthquake

Our united front: PrimeVigilance response to Zagreb earthquake

Published
23 March 2020.

Read more
 
NEWS – A Message from Ergomed plc Executive Chairman Dr Miroslav Reljanovic : Ergomed Response to COVID-19

Our United Front : Ergomed Plc Response to COVID-19 

Published
21 March 2020.

Read more
 
PRESS RELEASE – Ergomed Announces Provision of Clinical Research Services for COVID-19 Clinical Study

Guildford, UK – 18 March 2020: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces the initiation of a study of siltuximab, an interleukin (IL)-6 targeted monoclonal antibody, for the treatment of patients with COVID-19 who have developed serious respiratory complications (Siltuximab In Serious COVID-19; SISCO Study). The study is sponsored by the Papa Giovanni XXIII Hospital in Bergamo, Italy and supported by EUSA Pharma (EUSA) (see announcement below).

Published
18 March 2020.

Read more

This site uses cookies to personalise and customise your experience. No cookies collect personal or sensitive information. By clicking “I Accept", you consent to cookies in accordance with our cookie policy.